

Media release

Ypsomed opens new tool manufacturing facility in Solothurn

Burgdorf, 21.04.2026, 7 a.m. – Ypsomed opened its new tool manufacturing facility in Solothurn on Monday, thereby expanding its capacity for the design and manufacture of plastic injection molds for pens and autoinjectors. In addition to its existing tool shop in Burgdorf, Ypsomed will now also manufacture tools in Solothurn for its production facilities in Switzerland, Germany, China, and, starting in 2027, the United States.

To meet the growing global demand for injection systems and offer customers the highest quality, the capacity for manufacturing new injection molds will be significantly increased. Tool manufacturing is a core component of the production of pens and autoinjectors. The precision and complexity required in the creation of these tools are fundamental to the entire manufacturing process. The team at the new tool manufacturing facility comprises 35 employees, plus apprentices, and is set to be gradually expanded to around 100 employees and apprentices. With this, Ypsomed is doubling its personnel capacity in this area. Ypsomed trains a total of 20 industrial mechanics and 10 design engineers at its locations in Burgdorf and Solothurn.

“The investment in the new tool manufacturing facility in Solothurn is a clear commitment to the development of our sites in Switzerland,” said Simon Michel, CEO of Ypsomed, at the grand opening ceremony with the participating companies. “Tool manufacturing is the backbone of the high-precision manufacturing of our pens and autoinjectors.” A state-of-the-art infrastructure has been created here in ten months of construction. Approximately 25 million Swiss francs were invested in the renovation and in a new machine tool park.

Ypsomed invests nationally and internationally

The opening of the new tool manufacturing is the first milestone in a site development investment package totaling approximately 200 million Swiss francs. In the coming months, two new high-volume assembly lines and the associated injection molding machines for autoinjectors will be commissioned. In addition, a new fully automated high-bay warehouse is being built at the Solothurn site and is scheduled for completion by the end of 2027. Opposite the main entrance on Ziegelmatthstrasse, the Ypsomed Forum – a medium-sized conference center with space for approximately 300 guests – is being constructed in parallel.

Internationally, Ypsomed is also consistently pursuing its growth strategy to meet the rising demand for self-injection systems and further strengthen its customer focus. Last year, the company opened its first own manufacturing facility in Changzhou, China, and began expanding its production site in Schwerin, Germany. Additionally, construction is currently underway on a new site in Holly Springs, North Carolina (USA).

Contact

Michelle Roth, Head of Corporate Communication, Ypsomed Group
+41 79 643 65 45, michelle.roth@ypsomed.com

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years,

Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.

Ypsomed Holding AG

Brunnmattstrasse 6

3401 Burgdorf

www.ypsomed.com